[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2023128630A1 - Composition cosmétique améliorant la peau comprenant un extrait d'elaeocarpus sylvestris var. ellipticus (thunb.) hara - Google Patents

Composition cosmétique améliorant la peau comprenant un extrait d'elaeocarpus sylvestris var. ellipticus (thunb.) hara Download PDF

Info

Publication number
WO2023128630A1
WO2023128630A1 PCT/KR2022/021554 KR2022021554W WO2023128630A1 WO 2023128630 A1 WO2023128630 A1 WO 2023128630A1 KR 2022021554 W KR2022021554 W KR 2022021554W WO 2023128630 A1 WO2023128630 A1 WO 2023128630A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
effect
extract
composition
group
Prior art date
Application number
PCT/KR2022/021554
Other languages
English (en)
Korean (ko)
Inventor
강세찬
정용준
황재성
전혜린
김태희
Original Assignee
주식회사 제넨셀
주식회사 인비보텍
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 제넨셀, 주식회사 인비보텍 filed Critical 주식회사 제넨셀
Priority claimed from KR1020220187384A external-priority patent/KR20230101739A/ko
Publication of WO2023128630A1 publication Critical patent/WO2023128630A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to a cosmetic composition for skin improvement containing an extract of dampalsu.
  • the skin is the largest organ in the body, always in contact with the outside, and plays a role as a protective film to protect the living body from various stimuli or dry environments. In addition, it plays a very important role in protecting against physical abrasions, preventing loss of water in the body, protecting from harmful ultraviolet rays from the sun, and regulating body temperature.
  • MMP matrix metalloproteinase
  • Human skin color is genetically determined by the concentration and distribution of melanin in the skin, but is also influenced by environmental or physiological conditions such as solar ultraviolet rays, fatigue, and stress.
  • Melanin is produced through a non-enzymatic oxidation reaction after converting tyrosine, a kind of amino acid, into DOPA and dopaquinone by the action of an enzyme called tyrosinase.
  • Cosmetics are items used on the human body to clean and beautify the human body, add attractiveness, brighten the appearance, or maintain or promote the health of the skin and hair.
  • Demand for functional cosmetics is increasing, and the development of ingredients that are safe to the body, stable active ingredients, and, above all, exhibit excellent effects on skin regeneration, wrinkles, skin elasticity and whitening is required.
  • Dampalsu ( Elaeocarpus sylvestris var. ellipticus ) is an evergreen tree belonging to the Dampalsuaceae family that lives in Jeju Island and lives in the subtropical region including Jeju Island in Korea, southern China and southern Japan. It is lanceolate, thick, with shallow sawtooth on the edge, flowers bloom in July, white, arranged in racemes, fruits are drupes, ellipsoids, 2-2.5cm long, ripen in black purple in September.
  • the present inventors attempted to develop a cosmetic composition for relieving skin irritation, improving skin whitening, or preventing or improving skin wrinkles by analyzing various physiological activities using extracts of freshwater palm trees and compounds derived therefrom.
  • the present inventors have confirmed that the treatment with the extract of dampalsu exhibits anti-inflammatory effect, skin moisturizing effect, wrinkle improvement, skin whitening, anti-allergic effect, and skin damage protection or irritation relief effect, and based on this, the present invention was completed.
  • an object of the present invention is to provide a cosmetic composition for improving skin, a food composition, a quasi-drug composition, and a pharmaceutical composition for preventing or treating skin diseases, which contain an extract of fresh water.
  • Another object of the present invention is a cosmetic for skin improvement comprising at least one selected from the group consisting of compounds represented by Formulas 1 and 2 below, and cosmetically, food-wisely, and pharmaceutically acceptable salts thereof. It is to provide a composition, a food composition, a quasi-drug composition, and a pharmaceutical composition for preventing or treating skin diseases.
  • the present invention provides a cosmetic composition for skin improvement, a food composition, a quasi-drug composition, and a pharmaceutical composition for preventing or treating skin diseases, including an extract of fresh water.
  • the present invention is a cosmetic composition for skin improvement comprising at least one selected from the group consisting of the compounds represented by Formulas 1 and 2, and cosmetically, food-wisely, or pharmaceutically acceptable salts thereof. , It provides a food composition, a quasi-drug composition, and a pharmaceutical composition for preventing or treating skin diseases.
  • the freshwater extract is purified water, methanol, ethanol, propanol, butanol, ether, benzene, chloroform, It may be extracted with one or more solvents selected from the group consisting of ethylacetate, methylene chloride, hexane, cyclohexane, and mixed solvents thereof, but is not limited thereto. .
  • the freshwater extract may be extracted using any one part selected from the group consisting of freshwater leaves, stems, branches, and roots, but is not limited thereto.
  • the skin improvement effect may be any one or more selected from the group consisting of anti-inflammatory effect, skin moisturizing effect, wrinkle improvement, skin whitening, anti-allergic effect, and skin damage protection or irritation relief effect. , but is not limited thereto.
  • the composition can inhibit melanin production, but is not limited thereto.
  • the composition is softening lotion, astringent lotion, nutrient lotion, nutrient cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing foam, cleansing water, pack, powder, body lotion , Body cream, body oil, body essence, makeup base, foundation, hair dye, shampoo, rinse, and may be one or more selected from the group consisting of body cleanser, but is not limited thereto.
  • the food composition may be a health functional food composition, but is not limited thereto.
  • the skin disease may be any one or more selected from the group consisting of inflammatory skin disease, allergic skin disease and skin pigmentation disease, but is not limited thereto.
  • the present invention provides a cosmetic composition for skin improvement containing an extract of dampalsu.
  • the freshwater extract is purified water, methanol, ethanol, propanol, butanol, ether, benzene, chloroform, It may be extracted with one or more solvents selected from the group consisting of ethylacetate, methylene chloride, hexane, cyclohexane, and mixed solvents thereof, but is not limited thereto. .
  • the freshwater extract may be extracted using any one part selected from the group consisting of freshwater leaves, stems, branches, and roots, but is not limited thereto.
  • the skin improvement effect is selected from the group consisting of anti-inflammatory effect, skin moisturizing effect, wrinkle improvement, skin whitening, anti-allergic effect, melanin production inhibitory effect, and skin damage defense or irritation relief effect It may be any one or more, but is not limited thereto.
  • the present invention provides a cosmetic composition for skin improvement comprising at least one selected from the group consisting of compounds represented by Formulas 1 and 2, and cosmetically acceptable salts thereof.
  • the skin improvement effect is selected from the group consisting of anti-inflammatory effect, skin moisturizing effect, wrinkle improvement, skin whitening, anti-allergic effect, melanin production inhibitory effect, and skin damage defense or irritation relief effect It may be any one or more, but is not limited thereto.
  • the present invention provides a pharmaceutical composition for preventing or treating skin diseases, comprising an extract of dampalsu.
  • the freshwater extract is purified water, methanol, ethanol, propanol, butanol, ether, benzene, chloroform, It may be extracted with one or more solvents selected from the group consisting of ethylacetate, methylene chloride, hexane, cyclohexane, and mixed solvents thereof, but is not limited thereto. .
  • the freshwater extract may be extracted using any one part selected from the group consisting of freshwater leaves, stems, branches, and roots, but is not limited thereto.
  • the skin disease may be any one or more selected from the group consisting of inflammatory skin disease, allergic skin disease and skin pigmentation disease, but is not limited thereto.
  • the skin disease is atopic dermatitis, contact dermatitis, acne, seborrheic dermatitis, heat rash, urticaria, psoriasis, scleroderma, eczema, vitiligo, lupus, acne, and systemic lupus erythematosus, allergic Dermatitis, asthma, chronic idiopathic urticaria, allergic contact dermatitis, melasma, freckles, lentigines, age spots, moles, milk coffee spots, nevus of Ota, nevus blue, hyperpigmentation spots, hyperpigmentation after drug use, brown spots of pregnancy ( gravidic chloasma), and post-inflammatory pigmentation due to wounds or dermatitis, but is not limited thereto.
  • the present invention provides a pharmaceutical composition for preventing or treating skin diseases comprising at least one selected from the group consisting of compounds represented by Formulas 1 and 2, and pharmaceutically acceptable salts thereof.
  • the skin disease may be any one or more selected from the group consisting of inflammatory skin disease, allergic skin disease and skin pigmentation disease, but is not limited thereto.
  • the skin disease is atopic dermatitis, contact dermatitis, acne, seborrheic dermatitis, heat rash, urticaria, psoriasis, scleroderma, eczema, vitiligo, lupus, acne, and systemic lupus erythematosus, allergic Dermatitis, asthma, chronic idiopathic urticaria, allergic contact dermatitis, melasma, freckles, lentigines, age spots, moles, milk coffee spots, nevus of Ota, nevus blue, hyperpigmentation spots, hyperpigmentation after drug use, brown spots of pregnancy ( gravidic chloasma), and post-inflammatory pigmentation due to wounds or dermatitis, but is not limited thereto.
  • the present invention provides a skin improvement method comprising the step of treating the skin of a subject in need of the freshwater extract.
  • the skin improvement effect is selected from the group consisting of anti-inflammatory effect, skin moisturizing effect, wrinkle improvement, skin whitening, anti-allergic effect, melanin production inhibitory effect, and skin damage defense or irritation relief effect It may be any one or more, but is not limited thereto.
  • the present invention provides a skin improvement method comprising the step of treating the skin of a subject in need thereof with at least one selected from the group consisting of compounds represented by Formulas 1 and 2, and cosmetically acceptable salts thereof. to provide.
  • the skin improvement effect is selected from the group consisting of anti-inflammatory effect, skin moisturizing effect, wrinkle improvement, skin whitening, anti-allergic effect, melanin production inhibitory effect, and skin damage defense or irritation relief effect It may be any one or more, but is not limited thereto.
  • the present invention provides a skin disease treatment method comprising the step of treating the skin of a subject in need thereof with a freshwater extract.
  • the present invention is a skin disease treatment method comprising the step of treating the skin of a subject in need thereof with at least one selected from the group consisting of compounds represented by Formulas 1 and 2, and pharmaceutically acceptable salts thereof.
  • the present invention provides a use of a freshwater extract in the manufacture of a drug for skin improvement, prevention or treatment of skin diseases.
  • the present invention provides the use of the compounds represented by Chemical Formulas 1 and 2, or pharmaceutically acceptable salts thereof, in the preparation of drugs for improving skin, preventing or treating skin diseases.
  • the freshwater extract according to the present invention and/or the compounds of Formulas 1 and 2 according to the present invention are not toxic to the skin, but have anti-inflammatory effect, skin moisturizing effect, wrinkle improvement, skin whitening, anti-allergic effect, and skin damage protection or stimulation. It was confirmed that it has an alleviating effect and exhibits a skin improvement effect through various mechanisms. Accordingly, it can be used in a variety of ways, including a cosmetic composition for skin improvement, a food composition, and a quasi-drug composition, as well as a composition for preventing or treating skin diseases.
  • 1a and 1b are graphs showing the results of HPLC analysis of compound 1 and compound 2 derived from an octal water alcohol extract.
  • 2a to 2c are graphs showing the results of the cytotoxicity test of the extract of sagebrush extract and/or compound 1 and compound 2 on HaCaT cells, NIH3T3 cells, and RBL-2H3 cells.
  • 3a and 3b are graphs showing the inhibitory effect of sagebrush extract on TNF- ⁇ mRNA expression under LPS or UV stimulation.
  • 4a and 4b are graphs showing the inhibitory effect of sagebrush extract on IL-1 ⁇ mRNA expression under LPS or UV stimulation.
  • 5 is a graph showing the activity of increasing the expression of AQP3 and HAS3 in a concentration-dependent manner of an extract of sagebrush.
  • 6a to 6d are western blot test results and graphs showing the effect of p-38, p-JNK, and p-I ⁇ B ⁇ expression suppression effect of sagebrush extract.
  • FIG. 7a and 7c are graphs showing the inhibitory effects of extracts of freshwater ethanol on MMP-1 and MMP-12 expression
  • FIG. 7b is a graph showing the inhibitory effects of extracts on freshwater ethanol, compound 1 and compound 2 on MMP-9 expression.
  • 9a and 9b are graphs showing the inhibitory effects of p-ERK, c-fos, and c-Jun of the extract of sagebrush.
  • Figure 10a is a graph showing the inhibitory effect of inflammatory cytokines (TNF- ⁇ and IL-1 ⁇ ) of the extract of daffodil alcohol.
  • FIG. 10B is a graph and results of Western blotting experiments showing the c-Jun and p-JNK inhibitory effects of the sagebrush extract.
  • FIG. 11 is a graph showing concentration-dependent ⁇ -Hexosaminidase inhibitory effects of sagebrush extract, compound 1, and compound 2.
  • 12a and 12b are graphs and photographs showing the skin whitening effect according to the treatment with the daffodil extract in the artificial skin model.
  • 13a and 13b are photographs and graphs showing the effect of improving wrinkles by treatment with a quartet extract when wrinkles are induced by UVB in an artificial skin model.
  • 14a to 14c are graphs showing the results of representative images, transepidermal water loss, and skin erythema on the protective effect of sagebrush extract on human skin damage under external stimulation (chemical, product) conditions.
  • 15a to 15d are graphs showing the results of representative images, visual evaluation, transepidermal water loss, and skin erythema on the mitigating effect of sagebrush extract on human skin damage under external stimulation (skin irritation induction, 1% SLS) conditions.
  • the present invention provides a cosmetic composition for skin improvement containing an extract of dampalsu.
  • extract refers to an extract obtained by the extraction treatment of fresh water, a diluted or concentrated liquid of the extract, a dried product obtained by drying the extract, a crude or purified product of the extract, or a mixture thereof. It includes extracts of all formulations that can be formed using the extract itself and the extract solution. In addition, a crude extract, a polar solvent-soluble extract, or a non-polar solvent-soluble extract may be included.
  • the method for extracting the freshwater water is not particularly limited, and can be extracted according to a method commonly used in the art.
  • a method using an extraction device such as supercritical extraction, subcritical extraction, high-temperature extraction, high-pressure extraction, or ultrasonic extraction, or a method using an adsorption resin including XAD and HP-20 may be used.
  • Non-limiting examples of the extraction method include a heating extraction method, a cold extraction method, a reflux cooling extraction method, a steam distillation method, an ultrasonic extraction method, an elution method, a compression method, and the like, which are performed alone or in combination of two or more methods. It can be.
  • the extract may be additionally subjected to a conventional fractionation process and may be purified according to a conventional purification method.
  • the extract included in the composition of the present invention may be prepared by pulverizing the primary extract extracted by the hot water extraction or solvent extraction method through an additional process such as distillation under reduced pressure and freeze drying or spray drying.
  • purified fractions can be additionally obtained from the primary extract through various chromatography. Therefore, in the present invention, the extract may include all extracts, separated compounds, fractions and purified products obtained in each step of extraction, fractionation or purification, dilution, concentration, or drying thereof.
  • the type of extraction solvent used for extracting the fresh water is not particularly limited, and according to a conventional method known in the art for extracting an extract from a natural product, that is, under normal temperature and pressure conditions. It can be extracted using a phosphorus solvent.
  • the freshwater extract is purified water, methanol, ethanol, propanol, butanol, ether, benzene, chloroform, ethyl acetate ( ethylacetate), methylene chloride, hexane, cyclohexane, and a mixed solvent thereof.
  • a lower alcohol such as methanol, ethanol, propanol, or butanol or an aqueous solution of a lower alcohol may be used as a solvent.
  • extraction may be performed using ethanol or aqueous ethanol solution as a solvent, but is not limited thereto.
  • ethanol when fresh water is extracted using ethanol as a solvent, for example, 10% to 100% ethanol, 10% to 90% ethanol, 10% to 80% ethanol, 10% to 70% ethanol, 10% to 70% ethanol 60% ethanol, 10% to 50% ethanol, 20% to 90% ethanol, 20% to 80% ethanol, 20% to 70% ethanol, 20% to 60% ethanol, 20% to 50% ethanol, 30% to 90% % Ethanol, 30% to 80% Ethanol, 30% to 70% Ethanol, 30% to 60% Ethanol, 30% to 50% Ethanol, 40% to 90% Ethanol, 40% to 80% Ethanol, 40% to 70% Ethanol, 40% to 60% ethanol, 40% to 50% ethanol, 45% to 55% ethanol, or 50% ethanol may be used, but is not limited thereto.
  • An aqueous solution of methanol, ethanol, propanol, or butanol may be used within the above-mentioned range.
  • the prepared extract may then be filtered or concentrated or dried to remove the solvent, and both filtration, concentration and drying may be performed.
  • filtration may use filter paper or a vacuum filter
  • concentration may use a vacuum vacuum concentrator or vacuum rotary evaporator
  • drying may be performed by vacuum drying, vacuum drying, boiling drying, spray drying, freeze drying, and the like.
  • vacuum drying vacuum drying, boiling drying, spray drying, freeze drying, and the like.
  • the number of extractions may be carried out one or more times, but as the extraction continues, the yield of the active ingredient significantly decreases, so it may not be economical to perform the extraction repeatedly five times or more. Accordingly, the number of extractions is preferably 1 to 5 times, and more preferably 2 to 5 repeated extractions, but is not limited thereto.
  • the freshwater extract may be extracted using any one part selected from the group consisting of freshwater leaves, stems, branches, and roots, but is not limited thereto.
  • the freshwater may be directly grown or commercially available without limitation.
  • the present invention provides a cosmetic composition for skin improvement comprising at least one selected from the group consisting of compounds represented by Formulas 1 and 2, and cosmetically acceptable salts thereof.
  • the compound represented by Formula 1 is [3,4,5,6-tetrakis[(3,4,5-trihydroxybenzoyl)oxy]oxan-2-yl] methyl 3,4,5-trihydroxybenzoate It may have an IUPAC name, a chemical formula of C 41 H 32 O 26 , and a molecular weight of 940.7. It may also be named Compound 1 in the present invention.
  • the compound represented by Formula 2 is (1R, 7R, 8S, 26R, 28S, 29R, 38R) -1,13,14,15,18,19,20,34,35,39, 39-undecahydroxy-2,5,10,23,31-pentaoxo-6,9,24,27,30,40-hexaoxaoctacyclo[34.3.1.0 4 , 38 .0 7 , 26 .0 8 , 29 .0 11 , 16 .0 17 , 22 .0 32 , 37 ]tetraconta-3,11,13,15,17,19,21,32,34,36-decaen-28-yl]3,4,5-trihydroxybenzoate IUPAC name It may have a chemical formula of C 41 H 28 O 27 and a molecular weight of 952.6. It may also be named Compound 2 in the present invention.
  • the method for obtaining the compound may be chemically synthesized by a method known in the field to which the present invention pertains, or a commercially available material may be used, but is not limited thereto.
  • a compound represented by Formula 1 or 2 may be included in the extract, but is not limited thereto.
  • the extract may contain a high dose of the compound, but is not limited thereto.
  • the skin improvement effect may be any one or more selected from the group consisting of anti-inflammatory effect, skin moisturizing effect, wrinkle improvement, skin whitening, anti-allergic effect, and skin damage protection or irritation relief effect, but is limited thereto It is not.
  • the causative agent of skin irritation is any one selected from the group consisting of lipopolysaccharide (LPS), ultraviolet (UV), sodium laureth sulfate (SLS), pollen, ultraviolet rays, fine dust, yellow dust, house dust mites, and heavy metals. It may be one or more, but is not limited thereto.
  • the composition is softening lotion, astringent lotion, nutrient lotion, nutrient cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing foam, cleansing water, pack, powder, body lotion, body cream, It may be characterized in that at least one selected from the group consisting of body oil, body essence, makeup base, foundation, hair dye, shampoo, rinse and body cleanser, but is not limited thereto.
  • cosmetics may be a concept including all things that make the appearance of the human body beautiful, but is not limited thereto, and may include the broadest meaning used in the art.
  • the cosmetic composition of the present invention can be used in cosmetics or as a cosmetic additive, and when the composition of the present invention is used as a cosmetic additive, it can be used to prepare a cosmetic composition for keeping hands or feet clean.
  • Examples include soap (solid soap, liquid soap, foam soap, body soap, hand soap, etc.), cleansing foam, shampoo (hair shampoo, dry shampoo, etc.), but are not limited thereto.
  • the cosmetic composition of the present invention can be prepared in any formulation commonly prepared in the art, for example, longevity (skin lotion), skin, skin softener, skin toner, astringent, solution, suspension, emulsion, paste , powder, gel, cream, hand cream, hand sanitizer, lotion, milk lotion, moisture lotion, nourishing lotion, body lotion, body cleanser, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax It may be formulated as a foundation, spray, and sheet, but is not limited thereto. More specifically, it may be formulated into a flexible lotion, nourishing lotion, nutrient cream, massage cream, moisture cream, essence, nutrient essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.
  • compositions of such formulations may be prepared according to conventional methods in the art.
  • the mixing amount of the additional ingredients such as the moisturizing agent can be easily selected by those skilled in the art within a range that does not impair the objects and effects of the present invention.
  • the composition may be prepared in the form of a general emulsion formulation and solubilization formulation.
  • Emulsified cosmetics include nutrition lotion, cream, essence, etc.
  • solubilized cosmetics include softening lotion.
  • the composition of the present invention is a solution, gel, solid or kneaded anhydrous product, emulsion obtained by dispersing an oil phase in an aqueous phase, suspension, emulsion, microemulsion, microcapsule, mask pack, microgranule or ionic form (liposome) , non-ionic vesicular dispersant form, cream, toner, lotion, powder, ointment, spray, paste, pack, face wash, soap, surfactant-containing cleansing, oil, powder foundation, bath powder, emulsion foundation, wax, It can be provided in the form of a foundation or concealer stick.
  • it can be prepared in the form of a foam (foam) or the form of an aerosol composition further containing a compressed propel
  • the formulation of the composition is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, etc. may be included as carrier components. there is.
  • lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, etc. may be included as carrier components, and in particular, in the case of a spray, additional chlorofluorohydrocarbon, propane /Propellants such as butane and dimethyl ether may be included.
  • the carrier component may include a solvent, a solubilizing agent, an emulsifying agent, and the like, and specifically, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, fatty acid ester of sorbitan, and the like may be included.
  • a solvent a solubilizing agent, an emulsifying agent, and the like, and specifically, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, fatty acid ester of sorbitan, and the like may be included.
  • a liquid diluent such as water, ethanol, or propylene glycol as a carrier component
  • suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester
  • Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, tracanth, and the like may be included.
  • the formulation of the composition is surfactant-containing cleansing
  • carrier components aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether Sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, ethoxylated glycerol fatty acid ester, and the like may be included.
  • blending components that may be added in addition to the above are not limited to the above examples, and any of the above ingredients can be blended within a range not impairing the objects and effects of the present invention, but preferably 0.01 to 10% by weight relative to the total weight. , more preferably 0.01-5% by weight percentage.
  • the cosmetic composition may further include functional additives and ingredients included in general cosmetic compositions in addition to the ingredients disclosed herein, and commonly used purified water, thickeners, preservatives, stabilizers, solubilizers, surfactants, carriers, and fragrances. or a combination thereof.
  • Alcohols, oils, surfactants, fatty acids, silicone oils, wetting agents, humectants, viscosity modifiers, emulsions, stabilizers, UV scattering agents, UV absorbers, coloring agents, perfumes, and the like may be exemplified as the carrier.
  • Compounds/compositions that can be used as the alcohol, oil, surfactant, fatty acid, silicone oil, wetting agent, humectant, viscosity modifier, emulsion, stabilizer, UV scattering agent, UV absorber, coloring agent, fragrance, etc. are already known in the art. Since there is, those skilled in the art can select and use an appropriate corresponding material / composition.
  • the cosmetic composition if necessary, sunscreen, antioxidants (butylhydroxyanisole, gallic acid propyl, ellisorbic acid, tocopheryl acetate, butylated hydroxytoluene, etc.), preservatives (methylparaben, butylparaben , propylparaben, phenoxyethanol, imidazolidinylurea, chlorphenesin, etc.), colorant, pH adjusting agent (triethanolamine, citric acid, citric acid, sodium citrate, malic acid, sodium malate, fumaric acid, sodium fumarate, succinic acid , sodium succinate, sodium hydroxide, sodium hydrogen phosphate, etc.), humectants (glycerin, sorbitol, propylene glycol, butylene glycol, hexylene glycol, diglycerin, betaine, glycereth-26, methylglue Seth-20, etc.) and lubricants may be further added.
  • antioxidants butylhydroxy
  • the composition may further include one or more known ingredients having a skin condition improving effect, and furthermore, may further include one or more materials commonly used in cosmetic compositions.
  • materials commonly used in cosmetic compositions Specifically, fatty substances, organic solvents, solubilizers, thickeners and gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers,
  • fatty substances organic solvents, solubilizers, thickeners and gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers
  • sequestering and chelating agents such as sequestering and chelating agents, preservatives, vitamins, blocking agents, humectants, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or any other ingredient commonly used
  • the composition may further include a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high-molecular peptides, high-molecular polysaccharides, and sphingolipids.
  • cosmetic composition of the present invention in addition to the above essential components, other ingredients normally formulated in cosmetics may be blended as necessary.
  • oil and fat components moisturizing agents, emollient agents, surfactants, organic and inorganic pigments, Powders, ultraviolet absorbers, preservatives, bactericides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, fragrances, blood circulation promoters, cooling agents, antiperspirants, purified water, and the like may be included.
  • skin improvement is the degree of skin irritation, skin moisturizing, skin wrinkles, skin brightness, transparency, skin allergic reaction, and skin damage protection or irritation relief when evaluating skin sensory properties in relation to the meaning of the improvement. It relates to improvement of the overall skin condition, such as reduction of skin inflammation (symptoms, levels, etc.), improvement of skin moisturization (increase of skin moisture, etc.), improvement of skin wrinkles (reduction or lightening of the number of skin wrinkles) Skin whitening (increased skin brightness, reduced blemishes, etc.), anti-allergy (reduced skin trouble caused by allergy, not worsened, etc.), defense against skin damage or alleviation of irritation (external skin irritation skin damage is minimized or the degree of skin damage caused by external skin stimulation is alleviated), skin protective barrier improvement, cell damage inhibition, or any action that makes the skin surface more elastic.
  • those due to suppression of skin damage caused by skin stimulation or improvement of skin surface film, wrinkle improvement or suppression of skin aging are all
  • skin damage defense or irritation relief refers to improving skin damage occurring in all layers including the dermis of the skin by external factors, and in particular, improving damage represented by the epidermis of the skin.
  • the present invention provides a food composition for skin improvement comprising a fresh water extract.
  • the present invention provides a food composition for skin improvement comprising at least one selected from the group consisting of compounds represented by Formulas 1 and 2, and food chemically acceptable salts thereof.
  • "food” means a natural product or processed product containing one or more nutrients, preferably means a state that can be eaten directly through a certain degree of processing process, and usually means As, it means to include all health functional foods, beverages, food additives and beverage additives.
  • the food composition may be a health functional food composition, but is not limited thereto.
  • the "functional food” is the same term as food for special health use (FoSHU), medicine processed to efficiently display bioregulatory functions in addition to nutritional supply, It means a food with high medical effect, and can be manufactured into tablets, capsules, pills, granules, powders, liquids, flakes, pastes, syrups, gels, jellies, bars, or film formulations.
  • “functionality” means obtaining useful effects for health purposes, such as adjusting nutrients for the structure and function of the human body or physiological functions.
  • the type of food There is no particular limitation on the type of food.
  • foods to which the above substances can be added include meat, sausages, bread, chocolates, candies, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice creams, various soups, beverages, tea, drinks,
  • alcoholic beverages and vitamin complexes and in particular, the food group or food composition with added value to act and express the function of the food in the usual sense for a specific purpose has a body control function related to the regulation of biological defense rhythm, disease prevention and recovery, etc. This includes all foods designed to sufficiently express
  • food additives relate to substances used in food additives, mixing, infiltration, and other methods in manufacturing, processing, or preserving food, and when taken for a long period of time, such as health functional foods, the human body should be harmless to
  • the food additive may be added to the composition of the present invention as it is or used together with other foods or food ingredients, and may be appropriately used according to a conventional method.
  • the mixing amount of the components may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment).
  • the composition of the present invention may be added in an amount of 15% by weight or less, or 10% by weight or less based on the raw material.
  • the amount may be less than the above range, and since there is no problem in terms of safety, the component may be used in an amount greater than the above range.
  • the composition may include various food supplements acceptable in food science, and may further include appropriate carriers, excipients, and diluents commonly used in food production.
  • composition of the present invention in addition to the above, various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, It may contain alcohol, a carbonating agent used in carbonated beverages, and the like.
  • composition of the present invention may contain fruit flesh for preparing natural fruit juice, fruit juice beverages and vegetable beverages. These components may be used independently or in combination.
  • the ratio of these additives is not very important, but is generally selected from the range of 0.01-0.20 parts by weight per 100 parts by weight of the composition of the present invention, but is not limited thereto, and is not limited thereto, and is optimal in any capacity depending on the type and function of the product used. can be
  • composition according to the present invention may be added to health drinks, and may contain various flavoring agents or natural carbohydrates as additional ingredients like conventional drinks.
  • natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrins and cyclodextrins, and sugar alcohols such as xylitol, sorbitol and erythritol.
  • sweetener natural sweeteners such as thaumatin and stevia extract, or synthetic sweeteners such as saccharin and aspartame may be used.
  • the ratio of the natural carbohydrate may be generally about 0.01-0.20g, or about 0.04-0.10g per 100 mL of the composition of the present invention, but is not limited thereto, and may be a general amount added in the art, or the present invention It may include the maximum range in order to improve the efficacy of the composition of, and may include an optimal, arbitrary dose considering the synergistic effect with other substances added together.
  • the freshwater extract or the compound of the present invention When used as a food additive, it may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to a conventional method.
  • the mixing amount of the components may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment).
  • the freshwater extract or the compound of the present invention when preparing food or beverage, may be added in an amount of 15% by weight or less, or 10% by weight or less based on the raw material.
  • the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount greater than the above range.
  • the health functional food may have an advantage of having a more excellent effect by ingesting it in the form of inner beauty food.
  • inner beauty refers to food referred to as 'eating cosmetics or beauty food', and refers to food that changes the skin constitution to be healthy by absorbing various ingredients good for the skin into the body, and skin type
  • cosmetics containing the cosmetic composition and inner beauty food containing the freshwater extract or the compound are mixed, the effect is significantly higher than that of using only cosmetics or drugs, thereby more effectively relieving skin irritation and improving skin whitening.
  • it may have the advantage of seeing an effect of improving skin wrinkles.
  • the present invention provides a quasi-drug composition for skin improvement containing an extract of dampalsu.
  • the present invention provides a quasi-drug composition for skin improvement comprising at least one selected from the group consisting of compounds represented by Formulas 1 and 2, and pharmaceutically acceptable salts thereof.
  • the term “quasi-drugs” refers to preparations used for sterilization, insecticide, and similar purposes for the prevention of infectious diseases described in Article 2, Subparagraph 7, Item C of the Pharmaceutical Affairs Act, and diagnoses, treats, improves, alleviates, and treats human or animal diseases. Alternatively, among items used for the purpose of prevention, it may refer to items with milder effects than pharmaceuticals.
  • the quasi-drugs may include external skin preparations and personal hygiene products.
  • the skin may include all skin parts of the body including the face, hands, arms, legs, feet, chest, stomach, back, buttocks, and scalp, but is not limited thereto.
  • the type or formulation of the quasi-drug composition of the present invention is not particularly limited, but may be a bandage, gauze, cotton wool, bandage, disinfectant cleanser, shower foam, gargreen, wet tissue, detergent soap, hand wash, humidifier filler, mask, filter filler, etc. there is.
  • the composition of the present invention When the composition of the present invention is included in a quasi-drug for skin condition improvement, the composition may be used as it is or used together with other quasi-drug ingredients, and may be appropriately used according to a conventional method.
  • the mixing amount of the active ingredient may be appropriately determined depending on the purpose of use, and the quasi-drug composition according to the present invention may contain 0.01% to 20% by weight of microorganisms, lysates thereof, culture solutions, or mixtures thereof based on the total weight of the composition. there is.
  • the external skin preparation may be a cream, gel, ointment, skin emulsifier, skin suspension, transdermal delivery patch, lotion, or a combination thereof.
  • the skin external preparation may be appropriately formulated according to the combination of ingredients used in conventional skin external preparations such as cosmetics and pharmaceuticals, and if necessary.
  • the external skin preparations include metal sequestering agents such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid, caffeine, tannin, bellapamil, licorice extract, glabridin, and calin.
  • Hot water extracts of fruits, various herbal medicines, tocopherol acetate, glycyrrhizic acid, tranexamic acid and its derivatives or salts, vitamin C, magnesium ascorbate phosphate, ascorbic acid glucoside, arbutin, kojic acid, glucose, fructose, Sugars, such as trehalose, etc. can also be mix
  • composition for external application for skin may include, but is not limited to, 0.00001% by weight to 80% by weight of microorganisms, their lysates, culture solutions, or mixtures thereof based on the total weight of the composition, and the addition of the above weight%, etc.
  • the content and type of added materials may include all amounts, mixing ratios, and materials generally added in the art.
  • the present invention provides a pharmaceutical composition for preventing or treating skin diseases, comprising an extract of dampalsu.
  • the present invention provides a pharmaceutical composition for preventing or treating skin diseases comprising at least one selected from the group consisting of compounds represented by Formulas 1 and 2, and pharmaceutically acceptable salts thereof.
  • the skin disease may be any one or more selected from the group consisting of inflammatory skin disease, allergic skin disease and skin pigmentation disease, but is not limited thereto.
  • the inflammatory skin disease consists of atopic dermatitis, contact dermatitis, acne, seborrheic dermatitis, heat rash, urticaria, psoriasis, scleroderma, eczema, vitiligo, lupus, acne, and systemic lupus erythematosus. It may be any one or more selected from the group, but is not limited thereto.
  • the allergic skin disease is allergic dermatitis (allergic dermatitis), atopic dermatitis (atopic dermatitis), asthma (asthma), chronic idiopathic urticarial (chronic idiopathic urticarial), and allergic contact dermatitis It may be any one or more selected from the group consisting of (allergic contact dermatitis), but is not limited thereto.
  • the skin pigmentation disease is melasma, freckles, lentigo, age spots, moles, milk coffee spots, nevus of Ota, nevus blue, hyperpigmentation spots, hyperpigmentation after drug use, brown spots of pregnancy (gravidic chloasma), and may be one or more selected from the group consisting of pigmentation after inflammation due to wounds or dermatitis, but is not limited thereto.
  • the pharmaceutical composition according to the present invention may further include suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
  • compositions according to the present invention are powders, granules, sustained-release granules, enteric granules, solutions, eye drops, elsilic agents, emulsions, suspensions, spirits, troches, perfumes, and limonadese, respectively, according to conventional methods.
  • tablets, sustained-release tablets, enteric tablets, sublingual tablets, hard capsules, soft capsules, sustained-release capsules, enteric capsules, pills, tinctures, soft extracts, dry extracts, fluid extracts, injections, capsules, perfusate It can be formulated and used in the form of external preparations such as warning agents, lotions, pasta agents, sprays, inhalants, patches, sterile injection solutions, or aerosols, and the external agents are creams, gels, patches, sprays, ointments, and warning agents.
  • lotion, liniment, pasta, or cataplasma may have formulations such as the like.
  • diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
  • Additives for the liquid formulation according to the present invention include water, dilute hydrochloric acid, dilute sulfuric acid, sodium citrate, sucrose monostearate, polyoxyethylene sorbitol fatty acid esters (tween esters), polyoxyethylene monoalkyl ethers, lanolin ethers, Lanolin esters, acetic acid, hydrochloric acid, aqueous ammonia, ammonium carbonate, potassium hydroxide, sodium hydroxide, prolamine, polyvinylpyrrolidone, ethyl cellulose, sodium carboxymethyl cellulose, and the like may be used.
  • a solution of white sugar, other sugars, or a sweetener may be used, and aromatics, coloring agents, preservatives, stabilizers, suspending agents, emulsifiers, thickeners, etc. may be used as necessary.
  • Purified water may be used in the emulsion according to the present invention, and emulsifiers, preservatives, stabilizers, fragrances, etc. may be used as needed.
  • tragacantha methylcellulose, carboxymethylcellulose, carboxymethylcellulose sodium, microcrystalline cellulose, sodium alginate, hydroxypropylmethylcellulose, HPMC 1828, HPMC 2906, HPMC 2910, etc. and, if necessary, surfactants, preservatives, stabilizers, colorants, and fragrances may be used.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations are prepared by mixing the extract with at least one excipient or the like.
  • lubricants such as magnesium stearate and talc are also used.
  • Liquid formulations for oral administration include suspensions, internal solutions, emulsions, syrups, etc., which include various excipients in addition to water and liquid paraffin, which are commonly used simple diluents.
  • Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents.
  • composition according to the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level is the type of patient's disease, severity, activity of the drug, It may be determined according to factors including sensitivity to the drug, administration time, route of administration and excretion rate, duration of treatment, drugs used concurrently, and other factors well known in the medical field.
  • the pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered single or multiple times. Considering all of the above factors, it is important to administer an amount that can obtain the maximum effect with the minimum amount without side effects, which can be easily determined by a person skilled in the art to which the present invention belongs.
  • the pharmaceutical composition of the present invention can be administered to a subject by various routes. All modes of administration can be envisaged, eg oral administration, subcutaneous injection, intraperitoneal administration, intravenous injection, intramuscular injection, paraspinal space (intrathecal) injection, sublingual administration, buccal administration, intrarectal insertion, vaginal It can be administered by intraoral insertion, ocular administration, otic administration, nasal administration, inhalation, spraying through the mouth or nose, dermal administration, transdermal administration, and the like.
  • the pharmaceutical composition of the present invention is determined according to the type of drug as an active ingredient together with various related factors such as the disease to be treated, the route of administration, the age, sex, weight and severity of the disease of the patient.
  • “individual” means a subject in need of treatment of a disease, and more specifically, a human or non-human primate, mouse, rat, dog, cat, horse, cow, etc. of mammals.
  • administration means providing a given composition of the present invention to a subject by any suitable method.
  • prevention refers to any action that suppresses or delays the onset of a desired disease
  • treatment means that the desired disease and its resulting metabolic abnormality are improved or improved by administration of the pharmaceutical composition according to the present invention. All actions that are advantageously altered are meant, and “improvement” means any action that reduces a parameter related to a target disease, for example, the severity of a symptom, by administration of the composition according to the present invention.
  • Compound 1 was analyzed using HP Compound 1 HPLC (Agilent 1260 series).
  • a Sunfile C18 (4.6 mm x 250 mm) column (particle size 5 ⁇ m) was used and maintained at a temperature of 35 °C at a flow rate of 1.0 mL/min.
  • Mobile phase is A (0.1% Formic acid) and B (Acetonitrile) 0-3 minutes (90:10, v/v) ⁇ 10-20 minutes (80:20, v/v) ⁇ 30 minutes (65:35 , v/v) ⁇ 38-39 minutes (10:90, v/v) ⁇ 40-50 minutes (90:10, v/v).
  • the injected concentration was 10 ⁇ L, and UV detection was performed at 280 nm and 320 nm.
  • Compound 1 was purchased from Chemfaces and used as a standard solution (7.81, 15.63, 31.25, 62.5, 125, 250 ⁇ g/mL). Formic acid, acetonitrile, and water used in the analysis were purchased from Fisher Scientific Korea in HPLC grade. The formula for calculating the content of compound 1 is shown in Equation 1 below. All analyzes were repeated three times and compound 1 was detected at 18.3-3 minutes, and the content was 1.71 mg/g at 280 nm and 3.52 mg/g at 320 nm.
  • Compound 2 was purchased from Chemfaces and used as a standard solution (3.15, 6.25, 12.5, 25, 50, 100 ⁇ g/mL). Acetonitrile and water used in the analysis were purchased in HPLC grade from Fisher Scientific Korea, potassium phosphate monobasic and phosphoric acid were purchased from Sigma Aldrich, and sodium 1-heptanesulfonate was purchased from Daejung. The formula for calculating the content of compound 2 is shown in Equation 2 below. All assays were repeated three times, and compound 2 was detected at 5.16 minutes, and the content was 154.2 mg/g.
  • Compound 1 and Compound 2 which are compounds derived from the extract of distilled water, are shown in FIGS. 1A and 1B.
  • HaCaT cells which are cancerous keratinocytes, were prepared to confirm the cytotoxicity of the smelt water extract.
  • HaCaT cells were grown in DMEM (Dulbecco's modified Eagle's medium, WelGENE) medium containing 10% fetal bovine serum (FBS, WelGENE) and 1% penicillin/streptomycin (P/S, WelGENE) at 37°C and 5% CO 2 conditions. cultured.
  • HaCaT cells were dispensed in a 96-well plate at a concentration of 1x10 4 cells/well, and then cultured in a 37°C, 5% CO 2 incubator for 24 hours.
  • the cells were treated and cultured for 24 hours. Then, washed with DPBS (Dulbecco's Phosphate-Buffered Saline), replaced with a culture medium containing 10% EZ-Cytox solution, incubated in cell culture conditions for 1 hour, and then measured by absorbance at 450 nm with an ELISA reader (Tecan). The cytotoxicity of the sagebrush extract was measured.
  • DPBS Dynamic phosphate-Buffered Saline
  • Mouse-derived fibroblasts (NIH3T3) were dispensed in 3 ⁇ 10 4 per well in a 96-well plate and cultured for 24 hours. The medium was discarded, washed with PBS, and replaced with a new medium that did not contain 10% FBS, and 6.25, 12.5, and 25 ⁇ g/mL of sagebrush extract and 1.25, 2.5, 5, 10, and 20 ⁇ g/mL of compounds 1 and 2, respectively. After treatment with ⁇ g/mL, the cells were cultured for 24 hours. Then, an MTT solution (3-(4,5-dimethyl thiazol2-yl)-2,5 diphenyl-2H-tetrazolium bromide) was added and incubated for 4 hours.
  • MTT solution 3-(4,5-dimethyl thiazol2-yl)-2,5 diphenyl-2H-tetrazolium bromide
  • DMSO dimethylsulfoxide
  • isopropanol isopropanol
  • a cytotoxicity assay was performed to confirm whether the sagebrush extract exhibited cytotoxicity in RBL-2H3 cells.
  • RBL-2H3 cells were cultured in DMEM containing 10% FBS and 1% P/S at 37 °C and 5% CO 2 conditions.
  • RBL-2H3 cells were each dispensed in a 96-well plate at a concentration of 1 ⁇ 10 4 Cells/well, and 6.25, 12.5, 25, 50, and 100 ⁇ g/mL of freshwater alcohol extract, compound 1, and compound 2 were added to PBS, respectively. It was diluted by concentration and cultured for 24 hours.
  • the cells were washed with DPBS, replaced with a medium containing 10% EZ-Cytox solution, and cultured, and absorbance was measured at 450 nm with a Multi-reader reader (TECAN) (Zurich, Switzerland).
  • TECAN Multi-reader reader
  • HaCaT cells were dispensed in a 6-well plate at 3.5x10 5 cells/well and cultured for 24 hours in a 37°C, 5% CO 2 incubator. Thereafter, the medium was removed, washed with DPBS, and the test substance was diluted in DMEM medium containing 2% FBS, followed by pretreatment for 6 hours. The medium was removed, and the test substance and fine dust were diluted together in DMEM medium containing 2% FBS and treated for 3 hours. Next, after washing with 1 mL of DPBS, RNAiso Plus was treated with 200 ⁇ L, and cells attached to the bottom were collected with a cell scraper. Chloroform was added in an amount of 1/5 of RNAiso Plus and vortexed.
  • prepRNA was synthesized into cDNA. After adding 1 ⁇ L of synthesized cDNA, 4 ⁇ L of PCR premix, 14 ⁇ L of DEPC DW, and 1 ⁇ L of CYP1A1 primer, it was put into a reverse transcriptase PCR machine to perform 25 to 30 cycles. The prepared 2% agarose gel was put into an electrophoresis device, and 10 ⁇ L of RT-PCR-completed DNA was loaded onto the gel.
  • the results of LPS stimulation are shown in FIG. 3a.
  • the TNF- ⁇ mRNA expression level decreased by 25.1% when 0.1 ⁇ g/mL of sagebrush extract was treated.
  • 39.4% decreased, and in the case of 10 ⁇ g/mL treatment, 52.1% decreased.
  • the results for UV stimulation are shown in FIG. 3B. Specifically, when compared to the TNF- ⁇ mRNA expression level when treated with UV of 30 mJ/cm 2 , the TNF- ⁇ mRNA expression level was reduced by 18.4% when 10 ⁇ g/mL of sagebrush extract was treated. Confirmed.
  • TNF- ⁇ expression was suppressed by up to 52% or more even with LPS stimulation and by about 20% even with UV stimulation, even with a small amount of sagebrush extract treatment.
  • the results of LPS stimulation are shown in FIG. 4a.
  • the mRNA expression level of IL-1 ⁇ when treated with 25 ⁇ M of dexamethasone used as a positive control was 57.8%. decreased.
  • the mRNA expression level of IL-1 ⁇ when treated with 25 ⁇ M of dexamethasone used as a positive control was 57.8%. decreased.
  • the 0.1 ⁇ g/mL of sagebrush extract was treated, it decreased by 37.9%, when treated with 1 ⁇ g/mL, 36.8%, and when treated with 10 ⁇ g/mL, it decreased by 55.2%.
  • the results for UV stimulation are shown in FIG. 4b.
  • the positive control group (dexamethasone 25 ⁇ M) decreased the IL-1 ⁇ mRNA expression level by 19.5%.
  • HaCaT cells were prepared and treated with TNF- ⁇ as a stimulant to confirm the expression of aquaporin-3 (AQP-3) and hyaluronic acid synthase-3 (HAS-3).
  • the damselfish ethanol extract was effective in p38, c-Jun N-terminal kinase (JNK), and NF-kappa-B inhibitor alpha (I ⁇ B ⁇ ) at concentrations of 10 and 25 ⁇ g/mL.
  • JNK c-Jun N-terminal kinase
  • I ⁇ B ⁇ NF-kappa-B inhibitor alpha
  • MMP-9 expression was decreased in the case of treatment with the dampalsu extract, compound 1, and compound 2 compared to the case of treatment with only TNF- ⁇ , which was confirmed to be a statistically significant effect.
  • compound 1, and compound 2 melanin production inhibitory effect was analyzed. Specifically, B16F10 cells were seeded in a 6-well plate at 1 ⁇ 10 5 per well and cultured for 72 hours under cell culture conditions. The medium was removed, the cells were washed with PBS, and the test solution and fresh medium were added and cultured. The medium was treated with ⁇ -MSH, which promotes the melanin production process. At this time, 12.5, 25, and 50 ⁇ g/mL of the extract of sagebrush, 2.5, 5, and 10 ⁇ g/mL of Compound 1 and Compound 2 were treated together with a-MSH, respectively.
  • arbutin which is well known as a whitening functional substance, was used as a control to compare melanin production inhibitory effects. Only a-MSH was treated as a positive control group, and an untreated group was used as a negative control group.
  • RNA extraction was performed using oligo (dT) primers with enzymes and buffers provided in the PrimeScript II 1st strand cDNA Synthesis kit.
  • qRT-PCR reactions were performed on a Quant StudioTM-3 Real-time PCR (Thermo Fisher) (Waltham, MA, USA) instrument, using a 2X Real-Time PCR Kit.
  • the sagebrush extract inhibited the inflammatory cytokines TNF- ⁇ and IL-1 ⁇ in a concentration-dependent manner, which was statistically significant (P ⁇ 0.05 or P ⁇ 0.01). .
  • the extract of sagebrush suppressed the expression of c-Jun and the activation of JNK, which was statistically significant (P ⁇ 0.01 or P ⁇ 0.001). It was confirmed that it exhibits a remarkably excellent anti-allergic effect through inhibition of JNK activation.
  • ⁇ -Hexosaminidase assay was performed to confirm the anti-allergic effect of the extract of sagebrush. Specifically, RBL-2H3 cells were dispensed in a 24-well plate at a concentration of 1 ⁇ 10 4 cells/well, and after overnight, the medium was replaced with 500 ⁇ L of a new medium. 2 ⁇ g/mL Rat Anti DNP-BSA IgE was treated with 25 ⁇ L of each well, reacted at 37°C for 4 hours, and then washed twice with 500 ⁇ L of PIPES I buffer after removing the medium. After washing, 180 ⁇ L of 1 x PIPES II buffer was added and incubated at 37°C for 10 minutes.
  • RBL-2H3 cells were sequentially stimulated using Nanocs 2,4-dinitrophenyl-bovine serum albumin (DNP-BSA) and anti-DNP-BSA with the extract of dappled water, compound 1, and compound 2. It was found to inhibit ⁇ -Hexosaminidase compared to the positive control, Ketotifen, which was confirmed to be statistically significant (P ⁇ 0.001).
  • the artificial skin model was cultured in an environment containing 5% CO 2 at 37°C.
  • the control group DMSO
  • positive control group Kojic acid 1%
  • test group Sweet water extract 0.16%
  • DMSO DMSO
  • paraffin-embedded tissue sections were stained with Hematoxylin, Eosin, and Fontana-masson. Color change of skin tissue was photographed in all treatment groups and analyzed using Adode Photoshop CC 2015 software (San Jose, USA).
  • Keraskin-FTTM, a 3D artificial skin model, and Keraskin-FTTM medium were purchased from BIOSOLUTION (Seoul, Korea).
  • the artificial skin model was cultured in an environment containing 5% CO 2 at 37°C.
  • UVB 250 mJ/cm 2
  • 40 ⁇ l of 0.1% of freshwater ethanol extract and 1 mM of control Retinoic Acid (RA) were treated, followed by 24 hours at 37°C and 5% CO 2 . cultured in an environment.
  • paraffin-embedded tissue sections were stained with hematoxylin and eosin. Tissue color changes were photographed in all treatment groups and analyzed using Adode Photoshop CC 2015 software (San Jose, USA).
  • test to evaluate the protective effect of human skin damage against external (chemical) stimuli when a formulation containing 0.1% of dampalsu ethanol extract was applied to the human body was commissioned to Marie DM Dermatology Research Institute, a clinical institution. Twenty female volunteers between the ages of 20 and 59 were evaluated for device measurement (transepidermal water loss) and skin erythema after using the product for 14 days and inducing skin surface damage. The test group was treated with the product to which 0.1% of the quaternary ethanol extract was added, and the control group was not treated with the quaternary ethanol extract. The components of the test group and control group are shown in Table 1.
  • the sagebrush extract had a statistically significant effect compared to the control group and the untreated group in the amount of transepidermal water loss and erythema of the skin against chemical external stimuli. It has been confirmed that the alcohol extract has an excellent protective effect on human skin damage against external stimuli caused by chemical products.
  • the sagebrush extract was found to have a statistically significant effect compared to the control group and the untreated group in visual evaluation, transepidermal water loss, and skin erythema evaluation against chemical external stimuli. As a result, it was confirmed that the extract of dampalsu alcohol was excellent in alleviating damage to human skin against chemically induced skin external irritation.
  • the freshwater extract according to the present invention and/or the compounds of Formulas 1 and 2 according to the present invention are not toxic to the skin, but have anti-inflammatory effect, skin moisturizing effect, wrinkle improvement, skin whitening, anti-allergic effect, and skin damage protection or stimulation. It was confirmed that it has an alleviating effect and exhibits a skin improvement effect through various mechanisms. Accordingly, it can be used in a variety of ways, including a cosmetic composition for skin improvement, a food composition, and a quasi-drug composition, as well as a composition for preventing or treating skin diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition cosmétique améliorant la peau comprenant un extrait d'Elaeocarpus sylvestris var. ellipticus (thunb.) hara. L'extrait alcoolique d'Elaeocarpus sylvestris var. ellipticus (thunb.) hara selon la présente invention et les formules chimiques 1 et 2 selon la présente invention peuvent être utilisés en tant que composition cosmétique pour améliorer la peau, en tant que composition alimentaire et en tant que composition de quasi-médicament, ainsi qu'en tant que composition pour prévenir ou traiter des maladies de la peau en ce qu'il a été confirmé que l'extrait et les formules chimiques ne présentent pas de toxicité vis-à-vis de la peau, tout en ayant un effet anti-inflammatoire, un effet hydratant de la peau, un effet d'atténuation des rides, un effet de blanchiment de la peau, un effet anti-allergique, et une protection contre les dommages cutanés ou un effet de soulagement des irritations, présentant ainsi un effet d'amélioration de la peau par l'intermédiaire de divers mécanismes.
PCT/KR2022/021554 2021-12-28 2022-12-28 Composition cosmétique améliorant la peau comprenant un extrait d'elaeocarpus sylvestris var. ellipticus (thunb.) hara WO2023128630A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2021-0190069 2021-12-28
KR20210190069 2021-12-28
KR10-2022-0187384 2022-12-28
KR1020220187384A KR20230101739A (ko) 2021-12-28 2022-12-28 담팔수 추출물을 포함하는 피부 개선용 화장료 조성물

Publications (1)

Publication Number Publication Date
WO2023128630A1 true WO2023128630A1 (fr) 2023-07-06

Family

ID=86999639

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/021554 WO2023128630A1 (fr) 2021-12-28 2022-12-28 Composition cosmétique améliorant la peau comprenant un extrait d'elaeocarpus sylvestris var. ellipticus (thunb.) hara

Country Status (1)

Country Link
WO (1) WO2023128630A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110078941A (ko) * 2009-12-31 2011-07-07 한림대학교 산학협력단 가래나무의 특이성분으로 알려져 있는 ＰＧＧ을 유효성분으로 염증유도 관련 분자（ＴＮＦ－α，ＩＦＮ－γ，ＴＮＦ－α＋ＩＦＮ－γ ａｎｄ ＴＰＡ）에 의한 피부 염증 질환 치료용 조성물
KR20160127137A (ko) * 2014-03-18 2016-11-02 그린파마 갈산 및 갈산 유도체의 미용학적 및 약제학적 용도
KR102001069B1 (ko) * 2017-09-27 2019-07-17 충북대학교 산학협력단 상록성 목본식물 추출물을 포함하는 염증성 피부질환 개선용 조성물
US20210069272A1 (en) * 2019-09-05 2021-03-11 Tci Co., Ltd. Methods for skin whitening, ultraviolet radiation protection and suppression of glycation using green mango extracts and compounds obtained therefrom
KR20210084981A (ko) * 2019-12-30 2021-07-08 주식회사 팜스킨 중금속 함유 미세먼지에 의해 손상된 피부 개선용 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110078941A (ko) * 2009-12-31 2011-07-07 한림대학교 산학협력단 가래나무의 특이성분으로 알려져 있는 ＰＧＧ을 유효성분으로 염증유도 관련 분자（ＴＮＦ－α，ＩＦＮ－γ，ＴＮＦ－α＋ＩＦＮ－γ ａｎｄ ＴＰＡ）에 의한 피부 염증 질환 치료용 조성물
KR20160127137A (ko) * 2014-03-18 2016-11-02 그린파마 갈산 및 갈산 유도체의 미용학적 및 약제학적 용도
KR102001069B1 (ko) * 2017-09-27 2019-07-17 충북대학교 산학협력단 상록성 목본식물 추출물을 포함하는 염증성 피부질환 개선용 조성물
US20210069272A1 (en) * 2019-09-05 2021-03-11 Tci Co., Ltd. Methods for skin whitening, ultraviolet radiation protection and suppression of glycation using green mango extracts and compounds obtained therefrom
KR20210084981A (ko) * 2019-12-30 2021-07-08 주식회사 팜스킨 중금속 함유 미세먼지에 의해 손상된 피부 개선용 조성물

Similar Documents

Publication Publication Date Title
WO2017222317A1 (fr) Composition ayant pour effet d'améliorer l'hydratation de la peau, d'éliminer la kératine cutanée, d'améliorer l'élasticité de la peau, d'inhiber l'érythème, d'atténuer les rides cutanées ou d'atténuer le photovieillissement cutané, contenant une ionone ou un sel de celle-ci comme ingrédient actif
WO2017146414A1 (fr) Composition pour l'hydratation de la peau et atténuation des rides cutanées, contenant du α-terpinéol en tant que substance active
WO2017213346A1 (fr) Composition contenant de la diosmine ou son sel comme ingrédient actif et présentant un effet d'amélioration de l'hydratation de la peau, d'exfoliation de la peau, de renforcement de l'élasticité de la peau, d'inhibition de l'érythème, de réduction des rides de la peau, ou de retardement du photovieillissement de la peau
WO2018004141A1 (fr) Composition ayant pour effet d'améliorer l'hydratation de la peau, d'exfolier la peau, d'améliorer l'élasticité de la peau, d'inhiber l'érythème, d'atténuer les rides cutanées ou d'atténuer le photovieillissement cutané, contenant, en tant qu'ingrédient actif, un ou plusieurs composés choisis dans le groupe constitué du cimène, de l'acide béhénique, du 2-méthoxynaphtalène, du thymol et de leurs sels
WO2014168433A2 (fr) Composition pour favoriser la croissance des cheveux, la régénération de la mélanine des cheveux gris et la régénération de la peau
WO2016117762A1 (fr) Composition contenant un extrait de groseille à maquereau ou du glutathion
WO2017142265A1 (fr) Composition contenant de l'acide adipique utilisé comme principe actif pour l'atténuation des rides de la peau et l'amélioration de l'élasticité de la peau
WO2018062820A1 (fr) Composition visant à prévenir la chute des cheveux et à en favoriser la pousse, comprenant un phytoœstrogène en tant que principe actif
WO2018080039A1 (fr) Composition destinée à prévenir la chute des cheveux ou à améliorer la croissance des cheveux, contenant un extrait de feuilles de soja de couleur jaune
WO2023128630A1 (fr) Composition cosmétique améliorant la peau comprenant un extrait d'elaeocarpus sylvestris var. ellipticus (thunb.) hara
WO2019168348A1 (fr) Composition de prévention de la chute des cheveux et de stimulation de la pousse des cheveux
WO2023022540A1 (fr) Composition de prévention de la perte de cheveux ou favorisant la pousse des cheveux comprenant un extrait de fleur de chardon-marie comme ingrédient actif
WO2022260454A1 (fr) Composition pour le traitement de la dermatite atopique ou le renforcement de la barrière cutanée ou la prévention du vieillissement de la peau, comprenant un extrait de forsythia velutina nakai
WO2015037855A1 (fr) Composition comprenant un extrait d'herbes combinées comprenant de l'acanthopanax koreanum naka et du crinum asiaticum var. japonicum présentant une activité de prévention de la calvitie et une activité de stimulation de la croissance capillaire
WO2017142368A2 (fr) Composition permettant de prévenir et de traiter une maladie cutanée allergique ou inflammatoire
WO2016122091A1 (fr) Composition pharmaceutique pour la prévention et le traitement de maladie allergique ou de dermatite de contact, comprenant un extrait de cymbidium comme principe actif
WO2021002642A1 (fr) Composition pour prévenir ou traiter la polyarthrite rhumatoïde, comprenant du venin de serpent
WO2012173383A2 (fr) Composition à usage externe pour l'épiderme, contenant en tant que principe actif du cryptotanshinone
WO2020256380A1 (fr) Composition de blanchiment de la peau comprenant de la carvone ou un sel de celle-ci en tant que principe actif
WO2012096463A2 (fr) Composition contenant un extrait végétal mélangé en tant que principe actif pour prévenir et améliorer une maladie de la peau allergique ou non allergique, et ses utilisations
WO2014088258A1 (fr) Composition pour améliorer l'état de la peau comprenant de l'acide vératrique ou un sel acceptable de celui-ci en tant que principe actif
WO2023277626A1 (fr) Composition pour l'amélioration de la peau, comprenant du 2-phloroeckol en tant que principe actif
WO2024101570A1 (fr) Composition antioxydante, anti-inflammatoire et anti-allergique contenant un extrait de stévia en tant que principe actif
KR20230101739A (ko) 담팔수 추출물을 포함하는 피부 개선용 화장료 조성물
WO2022231294A1 (fr) Composition destinée à prévenir, à atténuer ou à traiter la pigmentation de la peau

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22916771

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE